RFA
RXRX icon

Resurgent Financial Advisors’s Recursion Pharmaceuticals RXRX Stock Holding History

Resurgent Financial Advisors’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.67K Buy
+1,000
New +$3.33K ﹤0.01% 316

Other funds holding RXRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Resurgent Financial Advisors's RXRX Position: Q2 2026 in Review

Resurgent Financial Advisors increased its Recursion Pharmaceuticals (RXRX) stake by 2.7% in Q2 2026, buying an estimated $4K and bringing the position to 45,400 shares worth $167K. The position accounts for 0.05% of the portfolio, ranked #293.

Resurgent Financial Advisors first reported a position in RXRX in Q4 2025 and has held it in 3 quarters since. 342 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

  • Resurgent Financial Advisors held 45,400 shares of Recursion Pharmaceuticals worth $167K as of Q2 2026.
  • Resurgent Financial Advisors bought 1,200 Recursion Pharmaceuticals shares in Q2 2026, an estimated $4K.
  • Recursion Pharmaceuticals made up 0.05% of Resurgent Financial Advisors's portfolio in Q2 2026, its #293 holding.
  • Resurgent Financial Advisors first reported a position in Recursion Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • 342 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Resurgent Financial Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.